{"id":866020,"date":"2025-07-02T07:38:47","date_gmt":"2025-07-02T11:38:47","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-highlights-additional-phase-3-clinical-sites-including-los-angeles-cancer-network-and-smilow-cancer-hospital-at-yale-new-haven\/"},"modified":"2025-07-02T07:38:47","modified_gmt":"2025-07-02T11:38:47","slug":"briacell-highlights-additional-phase-3-clinical-sites-including-los-angeles-cancer-network-and-smilow-cancer-hospital-at-yale-new-haven","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-highlights-additional-phase-3-clinical-sites-including-los-angeles-cancer-network-and-smilow-cancer-hospital-at-yale-new-haven\/","title":{"rendered":"BriaCell Highlights Additional Phase 3 Clinical Sites Including Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven"},"content":{"rendered":"<div class=\"mw_release\">\n<ul type=\"disc\">\n<li style=\"text-align:justify\">\n          <strong><br \/>\n            <em>Together, Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven add 30 satellite locations to enroll patients in BriaCell\u2019s pivotal Phase 3 study<\/em><br \/>\n          <\/strong>\n        <\/li>\n<li style=\"text-align:justify\">\n          <strong><br \/>\n            <em>BriaCell\u2019s Phase 3 study currently has 58 active clinical sites across 15 states, including Smilow Cancer Hospital, Los Angeles Cancer Network, University of Arizona, DHR Health Oncology Institute, Sylvester Comprehensive Cancer Center, Cancer Care Northwest, Hematology Oncology Associates of Fredericksburg, Northwestern University, Manhattan Hematology\/Oncology Associates, New York Cancer &amp; Blood Specialists, and Texas Oncology-Baylor Charles A. Sammons Cancer Center<\/em><br \/>\n          <\/strong>\n        <\/li>\n<\/ul>\n<p align=\"justify\">PHILADELPHIA and VANCOUVER, British Columbia, July  02, 2025  (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, is pleased to announce the addition of two key large cancer centers to its ongoing pivotal Phase 3 clinical study (ClinicalTrials.gov as <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ELk5asFc4W_pTsyQ_74TVh24-Mzlu6753otmRhYbVjyY5sprIiAS-FCWSq69QBhEyHCx7x9gRWFsf1ZNn9YK9-cgazU5ZhbrMYHuLV8qXbsa_A-lrOs-_dwvbkvY30jW\" rel=\"nofollow\" target=\"_blank\">NCT06072612<\/a>): Los Angeles Cancer Network and Smilow Cancer Hospital at New Haven. Each has 15 satellite locations. BriaCell anticipates completing patient enrollment in late 2025 or early 2026 and may report top line data as early as H1-2026.<\/p>\n<p align=\"justify\">BriaCell\u2019s pivotal Phase 3 clinical study is evaluating BriaCell\u2019s lead clinical candidate, Bria-IMT\u2122, plus immune check point inhibitor (CPI) versus physician\u2019s choice in <u>a<\/u>dvanced metastatic <u>b<\/u>reast <u>c<\/u>ancer (Bria-ABC).<\/p>\n<p align=\"justify\">\u201cClinical investigator interest in our Phase 3 study has exceeded our expectations which has significantly expanded patient access to our treatment,\u201d stated Giuseppe Del Priore, MD, MPH, BriaCell\u2019s Chief Medical Officer. \u201cThis strong engagement reflects both the urgent unmet need in metastatic breast cancer and the dedication of our clinical partners.\u201d<\/p>\n<p align=\"justify\">Interim data will be analyzed once 144 patient events (deaths) occur, comparing the overall survival (OS) in patients treated with the Bria-IMT combination regimen versus those treated with physician\u2019s choice as the primary endpoint. Positive results of the pivotal Phase 3 study could result in full approval and marketing authorization for Bria-IMT in MBC patients. <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0vDgywfJ8oWMFDTfGYjt_3ATGMHPIq6Jl093j-IlehUCQn8sbGXXG7rnH_4Oblc7G5nvrh07OyM1Jw9rPnNaodCcUo9b2PCYj8DTY55wfHiM_URH-mLGAnAyfBjabZjLUHO3qxFQkjS8oTw9NaiRDSjkeZasEUhzIPOK61Z8LQ0JtcOKGeT6chpF6DZlgWAOJ7oibOxERqTFitHyYyX365a12zPry5_7ohmv_Ajx1FTz5K5CKiHKWqBtW2ZbVyhuJgxI0txVyCCOtlrgQN1GuLq_Hx2Wh4jKCSdGqC22LFI4HH7dAOBEtoKlexXAKzmMiJH6Clddz8HUkONt1OzKLs4InvjMm7X_AjdDsvm5yGo=\" rel=\"nofollow\" target=\"_blank\">BriaCell recently (ASCO 2025) announced positive Phase 2 survival data in a similar MBC patient population treated with the same Bria-IMT combination regimen<\/a>. The Bria-IMT combination regimen has received FDA Fast Track designation.<\/p>\n<p align=\"justify\">For additional information on BriaCell\u2019s pivotal Phase 3 study of Bria-IMT and an immune check point inhibitor in metastatic breast cancer, please visit ClinicalTrials.gov <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ELk5asFc4W_pTsyQ_74TVlZv-2VFwG5RAd1pTFl4bWSCvMV54SgiZbFSrCUT0G8XaiyT9CcrDI55Eazin3FNCPGVF0T1-7-wfZi-bFgJyyXgXDR8KqMlAbs_YnatwPJz\" rel=\"nofollow\" target=\"_blank\">NCT06072612<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>About BriaCell Therapeutics Corp.<\/strong>\n      <\/p>\n<p align=\"justify\">BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=FzQjyW-1YoPDO7kYEU3HKmsU5SmOLSybeO-JD1CFTV9F3v-yC_z4Z1vJKhdhP8vRFy6ntAhEakDGx8X5OF916OFgLu2vPSP3Vgkq42cPnZ8=\" rel=\"nofollow\" target=\"_blank\">https:\/\/briacell.com\/<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Safe Harbor<\/strong>\n      <\/p>\n<p align=\"justify\">This press release contains \u201cforward-looking statements\u201d that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontemplate,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cseek,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201ctarget,\u201d \u201caim,\u201d \u201cshould,\u201d \u201cwill,\u201d \u201cwould,\u201d or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements, including those about the anticipated completion date of patient enrollment for the Company\u2019s ongoing pivotal Phase 3 clinical study; the anticipated timeline for reporting top line data for the Company\u2019s pivotal Phase 3 study; the timing and results of interim data; and the final results of the pivotal Phase 3 study, are based on BriaCell\u2019s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading \u201cRisks and Uncertainties\u201d in the Company\u2019s most recent Management\u2019s Discussion and Analysis, under the heading \u201cRisk Factors\u201d in the Company\u2019s most recent Annual Information Form, and under \u201cRisks and Uncertainties\u201d in the Company\u2019s other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company&#8217;s profiles on SEDAR+ at <strong><u>www.sedarplus.ca<\/u><\/strong>\u00a0and on EDGAR at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=jD-ZuVHhpZ-iPY_bUCMyARLidZOkV6D54v3VsRLZ6JiRuJv098Nd5jrfmNSApaS27tkQRleONBUPFbDLBMjXvA==\" rel=\"nofollow\" target=\"_blank\"><strong>www.sec.gov<\/strong><\/a>. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.<\/p>\n<p align=\"justify\">Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.<\/p>\n<p align=\"left\">\n        <strong>Contact Information<\/strong>\n      <\/p>\n<p align=\"left\">\n        <strong>Company Contact:<\/strong><br \/>\n        <br \/>William V. Williams, MD<br \/>President &amp; CEO<br \/>1-888-485-6340<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Ybdsz0KjdVZ4N4g4dPNq2UosGDVflZvLm_gz0W7VyouV5n9QNSr-AswTOPchJCxpPmhgQPUxPLwS4XjuW3_tJSbcXaufTanlWw4GAv99Uqk=\" rel=\"nofollow\" target=\"_blank\">info@briacell.com<\/a>\u00a0<\/p>\n<p align=\"left\">\n        <strong>Investor Relations Contact:<\/strong><br \/>\n        <br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=YDMwQ4uOvkNVJRyhnD8utjczhObghsi4lyg_Ji3xewir8rXgH2W2sM3uNxy5o9gAZzmR6ZYbcI0onJr-1vMVtuNN3ZFW7vaialArOS6EbrM=\" rel=\"nofollow\" target=\"_blank\">investors@briacell.com<\/a>\n      <\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ4NzgxNCM3MDI4MDc1IzIwOTA2NTg=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/M2Y5OGQ3NWItY2FiOS00NWU4LWFmZmUtMjFmNDQ3MTRkY2YzLTExMDIyMjktMjAyNS0wNy0wMi1lbg==\/tiny\/BriaCell-Therapeutics-Corp-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Together, Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven add 30 satellite locations to enroll patients in BriaCell\u2019s pivotal Phase 3 study BriaCell\u2019s Phase 3 study currently has 58 active clinical sites across 15 states, including Smilow Cancer Hospital, Los Angeles Cancer Network, University of Arizona, DHR Health Oncology Institute, Sylvester Comprehensive Cancer Center, Cancer Care Northwest, Hematology Oncology Associates of Fredericksburg, Northwestern University, Manhattan Hematology\/Oncology Associates, New York Cancer &amp; Blood Specialists, and Texas Oncology-Baylor Charles A. Sammons Cancer Center PHILADELPHIA and VANCOUVER, British Columbia, July 02, 2025 (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-highlights-additional-phase-3-clinical-sites-including-los-angeles-cancer-network-and-smilow-cancer-hospital-at-yale-new-haven\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;BriaCell Highlights Additional Phase 3 Clinical Sites Including Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-866020","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>BriaCell Highlights Additional Phase 3 Clinical Sites Including Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-highlights-additional-phase-3-clinical-sites-including-los-angeles-cancer-network-and-smilow-cancer-hospital-at-yale-new-haven\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BriaCell Highlights Additional Phase 3 Clinical Sites Including Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Together, Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven add 30 satellite locations to enroll patients in BriaCell\u2019s pivotal Phase 3 study BriaCell\u2019s Phase 3 study currently has 58 active clinical sites across 15 states, including Smilow Cancer Hospital, Los Angeles Cancer Network, University of Arizona, DHR Health Oncology Institute, Sylvester Comprehensive Cancer Center, Cancer Care Northwest, Hematology Oncology Associates of Fredericksburg, Northwestern University, Manhattan Hematology\/Oncology Associates, New York Cancer &amp; Blood Specialists, and Texas Oncology-Baylor Charles A. Sammons Cancer Center PHILADELPHIA and VANCOUVER, British Columbia, July 02, 2025 (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, &hellip; Continue reading &quot;BriaCell Highlights Additional Phase 3 Clinical Sites Including Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-highlights-additional-phase-3-clinical-sites-including-los-angeles-cancer-network-and-smilow-cancer-hospital-at-yale-new-haven\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-02T11:38:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ4NzgxNCM3MDI4MDc1IzIwOTA2NTg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-highlights-additional-phase-3-clinical-sites-including-los-angeles-cancer-network-and-smilow-cancer-hospital-at-yale-new-haven\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-highlights-additional-phase-3-clinical-sites-including-los-angeles-cancer-network-and-smilow-cancer-hospital-at-yale-new-haven\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"BriaCell Highlights Additional Phase 3 Clinical Sites Including Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven\",\"datePublished\":\"2025-07-02T11:38:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-highlights-additional-phase-3-clinical-sites-including-los-angeles-cancer-network-and-smilow-cancer-hospital-at-yale-new-haven\\\/\"},\"wordCount\":761,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-highlights-additional-phase-3-clinical-sites-including-los-angeles-cancer-network-and-smilow-cancer-hospital-at-yale-new-haven\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ4NzgxNCM3MDI4MDc1IzIwOTA2NTg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-highlights-additional-phase-3-clinical-sites-including-los-angeles-cancer-network-and-smilow-cancer-hospital-at-yale-new-haven\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-highlights-additional-phase-3-clinical-sites-including-los-angeles-cancer-network-and-smilow-cancer-hospital-at-yale-new-haven\\\/\",\"name\":\"BriaCell Highlights Additional Phase 3 Clinical Sites Including Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-highlights-additional-phase-3-clinical-sites-including-los-angeles-cancer-network-and-smilow-cancer-hospital-at-yale-new-haven\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-highlights-additional-phase-3-clinical-sites-including-los-angeles-cancer-network-and-smilow-cancer-hospital-at-yale-new-haven\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ4NzgxNCM3MDI4MDc1IzIwOTA2NTg=\",\"datePublished\":\"2025-07-02T11:38:47+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-highlights-additional-phase-3-clinical-sites-including-los-angeles-cancer-network-and-smilow-cancer-hospital-at-yale-new-haven\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-highlights-additional-phase-3-clinical-sites-including-los-angeles-cancer-network-and-smilow-cancer-hospital-at-yale-new-haven\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-highlights-additional-phase-3-clinical-sites-including-los-angeles-cancer-network-and-smilow-cancer-hospital-at-yale-new-haven\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ4NzgxNCM3MDI4MDc1IzIwOTA2NTg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ4NzgxNCM3MDI4MDc1IzIwOTA2NTg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-highlights-additional-phase-3-clinical-sites-including-los-angeles-cancer-network-and-smilow-cancer-hospital-at-yale-new-haven\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BriaCell Highlights Additional Phase 3 Clinical Sites Including Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BriaCell Highlights Additional Phase 3 Clinical Sites Including Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-highlights-additional-phase-3-clinical-sites-including-los-angeles-cancer-network-and-smilow-cancer-hospital-at-yale-new-haven\/","og_locale":"en_US","og_type":"article","og_title":"BriaCell Highlights Additional Phase 3 Clinical Sites Including Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven - Market Newsdesk","og_description":"Together, Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven add 30 satellite locations to enroll patients in BriaCell\u2019s pivotal Phase 3 study BriaCell\u2019s Phase 3 study currently has 58 active clinical sites across 15 states, including Smilow Cancer Hospital, Los Angeles Cancer Network, University of Arizona, DHR Health Oncology Institute, Sylvester Comprehensive Cancer Center, Cancer Care Northwest, Hematology Oncology Associates of Fredericksburg, Northwestern University, Manhattan Hematology\/Oncology Associates, New York Cancer &amp; Blood Specialists, and Texas Oncology-Baylor Charles A. Sammons Cancer Center PHILADELPHIA and VANCOUVER, British Columbia, July 02, 2025 (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, &hellip; Continue reading \"BriaCell Highlights Additional Phase 3 Clinical Sites Including Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-highlights-additional-phase-3-clinical-sites-including-los-angeles-cancer-network-and-smilow-cancer-hospital-at-yale-new-haven\/","og_site_name":"Market Newsdesk","article_published_time":"2025-07-02T11:38:47+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ4NzgxNCM3MDI4MDc1IzIwOTA2NTg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-highlights-additional-phase-3-clinical-sites-including-los-angeles-cancer-network-and-smilow-cancer-hospital-at-yale-new-haven\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-highlights-additional-phase-3-clinical-sites-including-los-angeles-cancer-network-and-smilow-cancer-hospital-at-yale-new-haven\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"BriaCell Highlights Additional Phase 3 Clinical Sites Including Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven","datePublished":"2025-07-02T11:38:47+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-highlights-additional-phase-3-clinical-sites-including-los-angeles-cancer-network-and-smilow-cancer-hospital-at-yale-new-haven\/"},"wordCount":761,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-highlights-additional-phase-3-clinical-sites-including-los-angeles-cancer-network-and-smilow-cancer-hospital-at-yale-new-haven\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ4NzgxNCM3MDI4MDc1IzIwOTA2NTg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-highlights-additional-phase-3-clinical-sites-including-los-angeles-cancer-network-and-smilow-cancer-hospital-at-yale-new-haven\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-highlights-additional-phase-3-clinical-sites-including-los-angeles-cancer-network-and-smilow-cancer-hospital-at-yale-new-haven\/","name":"BriaCell Highlights Additional Phase 3 Clinical Sites Including Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-highlights-additional-phase-3-clinical-sites-including-los-angeles-cancer-network-and-smilow-cancer-hospital-at-yale-new-haven\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-highlights-additional-phase-3-clinical-sites-including-los-angeles-cancer-network-and-smilow-cancer-hospital-at-yale-new-haven\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ4NzgxNCM3MDI4MDc1IzIwOTA2NTg=","datePublished":"2025-07-02T11:38:47+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-highlights-additional-phase-3-clinical-sites-including-los-angeles-cancer-network-and-smilow-cancer-hospital-at-yale-new-haven\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/briacell-highlights-additional-phase-3-clinical-sites-including-los-angeles-cancer-network-and-smilow-cancer-hospital-at-yale-new-haven\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-highlights-additional-phase-3-clinical-sites-including-los-angeles-cancer-network-and-smilow-cancer-hospital-at-yale-new-haven\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ4NzgxNCM3MDI4MDc1IzIwOTA2NTg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ4NzgxNCM3MDI4MDc1IzIwOTA2NTg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-highlights-additional-phase-3-clinical-sites-including-los-angeles-cancer-network-and-smilow-cancer-hospital-at-yale-new-haven\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"BriaCell Highlights Additional Phase 3 Clinical Sites Including Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/866020","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=866020"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/866020\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=866020"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=866020"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=866020"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}